TREASURE
Regimen
- Experimental
- Atezolizumab maintenance + thoracic radiotherapy (TRT)
- Control
- Atezolizumab maintenance alone
Population
Extensive-disease SCLC with any response to standard induction chemo-immunotherapy
Key finding
Protocol only — primary endpoint OS; safety interim planned after 23 TRT patients; trial later terminated for toxicity (not reported in this paper)
Source: PMID 36153496
Timeline
Guideline citations
- CSCO SCLC 2025 (p.68)⚠️ OCR source